临床肝胆病杂志2025，Vol.41Issue(7)：1246-1250,5.DOI:10.12449/JCH250702
胆汁淤积性肝病的临床管理
Clinical management of cholestatic liver disease
郭悦承 1蔡晓波 1陆伦根1
作者信息
- 1. 上海交通大学医学院附属第一人民医院消化内科,上海 200080
- 折叠
摘要
Abstract
Cholestatic liver disease(CLD)is a group of hepatobiliary disorders caused by impaired bile production,secretion,or excretion.With the application of liquid biopsy,multi-parameter radiological examination,and genomics technology,significant progress has been made in the diagnosis and prognostic evaluation of CLD.At present,the therapeutic principles for CLD mainly focus on addressing the underlying causes and managing cholestasis,and commonly used drugs include ursodeoxycholic acid,S-adenosylmethionine,cholestyramine,fibrates,and obeticholic acid.Based on the latest clinical consensus statements and research advances in CLD,this article systematically elaborates on the clinical management strategies for CLD from the aspects of diagnosis,treatment,and prognostic evaluation.关键词
胆汁淤积/熊去氧胆酸/奥贝胆酸Key words
Cholestasis/Ursodeoxycholic Acid/Obeticholic Acid引用本文复制引用
郭悦承,蔡晓波,陆伦根..胆汁淤积性肝病的临床管理[J].临床肝胆病杂志,2025,41(7):1246-1250,5.
